Actavis plc / Allergan plc

Dry Eye Disease / Ophthalmology

16M US cases/yr · $4.5B US Rx Eye Care Market (2014) · $1.6B Restasis Revenue (2014)

Disease Overview

Restasis (cyclosporine ophthalmic) was the first and only prescription treatment for chronic dry eye disease, generating $1.6B annually with no direct competitor. Combined with Allergan's glaucoma franchise (Lumigan, Alphagan, Combigan), the eye care portfolio was the second major value driver in the deal.

Competitive Landscape

Restasis had patent protection that Allergan aggressively defended (including the controversial sovereign immunity strategy with the Saint Regis Mohawk Tribe). Generic competition eventually arrived in 2022. The dry eye market has since expanded with Xiidra (Novartis/Bausch), Cequa (Sun Pharma), and Tyrvaya (Viatris). Allergan's glaucoma drugs faced biosimilar/generic competition but maintained franchise value.

Womens Health

Competitive Landscape

Lo Loestrin Fe (norethindrone acetate/ethinyl estradiol/ferrous fumarate) competes in the US oral contraceptive market, differentiated by its ultra-low 10-mcg ethinyl estradiol dose. The market is structurally dominated by low-cost generic combined oral contraceptives (COCs), creating persistent price and formulary pressure. Within the combined estrogen-progestin oral class, direct branded competitors include Yaz and Yasmin (drospirenone/ethinyl estradiol, Bayer) and Beyaz (drospirenone/EE/levomefolate); Loestrin and Minastrin 24 Fe (norethindrone/EE, Allergan legacy brands, now genericized); and Lo Minastrin Fe. Progestin-only pills (norethindrone, e.g., Ortho Micronor and generics) represent an adjacent oral MOA used for breastfeeding or estrogen-contraindicated patients; Opill (norgestrel, Perrigo) became the first FDA-approved OTC oral contraceptive in 2023. Non-oral hormonal competitors compete on adherence: Nexplanon (etonogestrel implant, Organon), the Mirena/Kyleena/Liletta/Skyla levonorgestrel IUDs, the copper ParaGard IUD (non-hormonal), and the NuvaRing/Annovera vaginal rings. A newer class entrant, Nextstellis (drospirenone/estetrol, Mayne Pharma), offers a natural estrogen (E4) differentiation. Commercial-lead read: Lo Loestrin Fe's low-dose positioning provides tolerability differentiation, but the category is generic-heavy and increasingly pressured by LARCs (IUDs/implants) and the first OTC oral entrant.

CNS / Alzheimers Disease

Competitive Landscape

Namenda XR (memantine ER) competes within a symptomatic Alzheimer's disease market that is now heavily genericized and is being disrupted by a new disease-modifying biologic class. In the symptomatic MOA cohort, acetylcholinesterase inhibitors are the dominant competitor class: Aricept (donepezil, Eisai/Pfizer), Exelon (rivastigmine, Novartis patch and oral), and Razadyne (galantamine, J&J) are all long-genericized and remain first-line for mild-to-moderate AD. Within memantine's own NMDA receptor antagonist class, generic memantine (multiple manufacturers) and the fixed-dose combination Namzaric (memantine/donepezil, Allergan) are direct intraclass competitors; Namenda XR itself lost exclusivity. The disruptive competitive class is anti-amyloid monoclonal antibodies targeting disease modification in early AD: Leqembi (lecanemab, Biogen/Eisai) received full FDA approval in July 2023 and Kisunla (donanemab, Lilly) received FDA approval in July 2024; the earlier Aduhelm (aducanumab, Biogen) was discontinued in 2024. Commercial-lead read: Namenda XR is effectively a generic-exposed symptomatic asset; the franchise-level threat is not direct MOA substitution but category shift as reimbursement and prescribing move toward anti-amyloid disease-modifying therapies in earlier-stage patients, compressing late-stage symptomatic volume over time.

Gastroenterology (IBS)

Competitive Landscape

Linzess (linaclotide) competes in the IBS-with-constipation (IBS-C) and chronic idiopathic constipation (CIC) markets, where branded prescription share is split across three distinct MOA classes. In the guanylate cyclase-C (GC-C) agonist class itself, Trulance (plecanatide, Salix/Bausch) is the direct in-class competitor, approved for CIC (2017) and IBS-C (2018). The chloride channel activator class is represented by Amitiza (lubiprostone, Takeda/Sucampo), approved for CIC, IBS-C in women, and opioid-induced constipation; generic lubiprostone has been available since 2020, eroding branded pricing. The sodium/hydrogen exchanger 3 (NHE3) inhibitor class is represented by Ibsrela (tenapanor, Ardelyx), approved in 2019 for IBS-C, positioned as a non-GC-C oral alternative. For IBS-with-diarrhea (IBS-D), a separate but adjacent franchise, competitors include Viberzi (eluxadoline, AbbVie/Allergan) - mixed mu-opioid agonist/delta antagonist - and Xifaxan (rifaximin, Salix), a non-absorbed antibiotic. Over-the-counter osmotic laxatives (polyethylene glycol 3350, e.g., MiraLAX) and prescription generics remain the default first-line layer below all branded options. Commercial-lead read: Linzess is the category leader by prescription volume, but faces one direct in-class branded competitor (Trulance), a newer MOA entrant (Ibsrela), and persistent generic/OTC pressure at the bottom of the treatment pyramid.

Chronic Migraine / Spasticity

Competitive Landscape

Botox Therapeutic (onabotulinumtoxinA) is the only botulinum toxin approved for chronic migraine prevention, but faces distinct MOA-class competition across the migraine preventive landscape and overlaps with other neurotoxins in spasticity. In chronic migraine, the dominant competitive class is anti-CGRP biologics: Aimovig (erenumab, Amgen/Novartis), Ajovy (fremanezumab, Teva), Emgality (galcanezumab, Lilly), and Vyepti (eptinezumab, Lundbeck) are all FDA-approved for migraine prevention and directly compete on a self- or IV-administered route without injection expertise. Small-molecule oral CGRP receptor antagonists (gepants) Qulipta (atogepant, AbbVie) and Nurtec ODT (rimegepant, Pfizer/Biohaven) are approved for migraine prevention and offer pill convenience. In spasticity (adult and pediatric upper/lower limb), Botox competes head-to-head with other neurotoxin acetylcholine-release inhibitors: Dysport (abobotulinumtoxinA, Ipsen), Xeomin (incobotulinumtoxinA, Merz), and Myobloc (rimabotulinumtoxinB, Supernus) all hold spasticity or related movement-disorder indications. Oral/intrathecal baclofen (GABA-B agonist) and tizanidine (alpha-2 agonist) remain standard-of-care generic alternatives in spasticity. Commercial-lead read: Botox's chronic-migraine franchise faces structural erosion from CGRP biologics and gepants, while spasticity remains competitive but neurotoxin-locked.